



@XMontalban

PROF. XAVIER MONTALBAN MD, PhD, FAAN, FEAN, FCAHS

Dr. Xavier Montalban is chair of the Department of Neurology-Neuroimmunology and director of the Multiple Sclerosis Centre of Catalonia at Vall d'Hebron University Hospital in Barcelona, as well as the chief of the Neuroimmunology Research Group at Vall d'Hebron Research Institute. From July 2017 to May 2020, he has been Professor of Medicine, the Director of the Division of Neurology at the University of Toronto and Director of the MS Centre at St Michael's Hospital.

Dr. Montalban received his medical license, trained as a neurology specialist and completed his PhD in neuroimmunology at the Universitat Autònoma de Barcelona. He went on to undertake a postdoctoral fellowship at the Lupus Research Institute, Guy's & St. Thomas' Hospital with additional clinical training at the National Hospital for Neurology and Neurosurgery, Queen Square in London, United Kingdom.

Dr. Montalban is the President of the Cemcat Foundation and former President and current Honorary Member of the Council of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). He the Vice Chair of the NMSS/Ectrimis Clinical Trials Committee and has been the Chair of the Medical & Scientific Board of the Multiple Sclerosis International Federation (MSIF). He is a Board member of the European Charcot Foundation and of the international initiative PROMS.

For the past twenty-five years, Dr. Montalban has been in the inception phases and on steering committees of many clinical trials related to multiple sclerosis. He has authored over 500 original and revision publications in international peer-reviewed journals plus several book chapters. He has been editor for the Clinical Cases Section of the Multiple Sclerosis Journal. Recently, he co-directed the development of the first ECTRIMS-EAN Multiple Sclerosis Treatment Guidelines.

His research interests include clinical trials, clinical aspects of MS, MR imaging and biological prognostic factors of disease evolution and treatment response, immunological mechanisms of the disease and other aspects of clinical management of MS. He has been exposed to a vast variety of neurological diseases in both sides of the Atlantic.

cem-cat.org
@cemcat_em